Dr. Spurgeon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3181 Sw Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-6101- Is this information wrong?
Education & Training
Oregon Health & Science UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009- Oregon Health & Science UniversityResidency, Internal Medicine, 2002 - 2006
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2002
Certifications & Licensure
OR State Medical License 2005 - 2025- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2009 Sep 01
- Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2011 Oct 01
- Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Start of enrollment: 2012 May 11
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsDiminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia.Chaitra Ujjani, Ted A Gooley, Stephen E Spurgeon, Deborah M Stephens, Catherine Lai, Catherine M Broome, Susan O'Brien, Haiying Zhu, Kerry J Laing, Allison M Winter, G...> ;Blood Advances. 2023 Sep 12
- 1 citationsA retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma.Titas Banerjee, Matthew Newman, Andy Chen, Richard T Maziarz, Levanto Schachter, Stephen E Spurgeon, Anusha Vallurupalli> ;Leukemia & Lymphoma. 2023 Jun 7
- 4 citationsPevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.Pallawi Torka, Swetha Kambhampati, Lu Chen, Xiaoguang Wang, Canping Chen, Dan Vuong, Hanjun Qin, Alexandra Muir, Kirsten Orand, Ivana Borja, D Lynne Smith, Alex F Herr...> ;Blood Cancer Journal. 2023 Jan 11
- Join now to see all
Abstracts/Posters
- SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Stephen E Spurgeon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in CLL Cells2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in CLL Cells2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hospital Affiliations
OHSU HospitalPortland, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
